Specify a stock or a cryptocurrency in the search bar to get a summary
Anebulo Pharmaceuticals Inc
214Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas. Address: 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734
Analytics
WallStreet Target Price
6 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 214
Dividend Analytics 214
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 214
Stock Valuation 214
Financials 214
Results | 2019 | Dynamics |